Preparation of β-Cyclodextrin Conjugated, Gelatin Stabilized SBA 15-CuInS2/ZnS Quantum Dot Nanocomposites for Camptothecin Release

Abstract

Camptothecin (CPT) is a potential anticancer drug. However, it faces challenges due to its poor water solubility and the need for an efficient drug release system. Herein, we developed a novel system composed of gelatin stabilized, mesoporous silica SBA15 encapsulated CuInS2/ZnS (CIS/ZnS) quantum dots (QDs) conjugated with β-cyclodextrin (β-CDs) for its potential use in the release of CPT. In this multifunctional system, β-CDs served as the drug carrier, SBA15 encapsulated QDs is capable of imaging and the gelatin was used to enhance the carrier-drug interaction. Fourier transform infrared (FTIR) analysis confirmed the successful conjugation of β-CDs to the Gel-SBA15 CIS/ZnS QDs, while optical analyses revealed excellent emission properties and high photostability. The β-CD-conjugated Gel-SBA15-CIS/ZnS QD nanocomposite was used to obtain the soluble derivate of CPT which further demonstrated a drug release profile following the triphasic model. Overall, the improved photostability and acceptable drug release profile of the β-CD conjugated Gel-SBA15-CIS/ZnS QD nanocomposite hold great promise for both imaging and therapeutic applications. Graphical Abstract

Advancements in semiconductor quantum dots: expanding frontiers in optoelectronics, analytical sensing, biomedicine, and catalysis

“…The drug release profile of the β-CD-conjugated Gel–SBA15–CIS/ZnS CQD nanocomposite was found to be acceptable, with 80% of the drug released over 9 hours, according to a triphasic model. 297 Monika Ruzycka-Ayoush customized a targeted drug delivery system using Ag–In–Zn–S CQDs modified with various molecules, including folic acid (FA), for selective drug administration to adenocarcinomic human alveolar basal epithelial cells (A549). The achievement of the lowest half-maximal inhibitory concentration (IC 50 ) indicates the efficiency of the drug delivery system.…”